Oramed Pharmaceuticals (ORMP) Interest Coverage Ratio (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Interest Coverage Ratio came in at 23.16 in Q1 2026, up 94.85% YoY from 11.88 in Q1 2025, and up 49.78% on a QoQ basis from 46.11 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Interest Coverage Ratio data on file, last reported at 23.16 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 94.85% year-over-year to 23.16 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.17 (up 93.7% YoY) and the FY2025 annual result came in at 63.39, down 17815.86% from the prior year.
- Interest Coverage Ratio climbed to 23.16 in Q1 2026, from 46.11 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.75 in Q4 2024 to a low of 520.8 in Q1 2023.
- A 5-year average of 75.41 and a median of 11.92 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio soared 233.23% — and 2025, when it slumped 8893.92%.
- Tracing ORMP's Interest Coverage Ratio over 5 years: stood at 141.68 in 2022, then surged by 99.07% to 1.32 in 2023, then soared by 233.23% to 1.75 in 2024, then sank by 2730.86% to 46.11 in 2025, then jumped by 49.78% to 23.16 in 2026.
- The last three Interest Coverage Ratio figures came in at 23.16 (Q1 2026), 46.11 (Q4 2025), and 18.11 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.30 |
| Mar 31, 2026 | -23.16 |
| Dec 31, 2025 | -46.11 |
| Sep 30, 2025 | -18.11 |
| Jun 30, 2025 | -18.57 |
| Mar 31, 2025 | -450.00 |
| Dec 31, 2024 | 1.75 |
| Sep 30, 2024 | -6.94 |
| Jun 30, 2024 | -12.01 |
| Mar 31, 2024 | -5.00 |
| Dec 31, 2023 | -1.32 |
| Sep 30, 2023 | -3.50 |
| Jun 30, 2023 | -4.99 |
| Mar 31, 2023 | -520.80 |
| Dec 31, 2022 | -141.68 |
| Sep 30, 2022 | -8.61 |
| Jun 30, 2022 | -11.02 |
| Mar 31, 2022 | -11.92 |
| Aug 31, 2021 | -3,027.88 |
| Nov 30, 2019 | -121.45 |